Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)

Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)

US Patent 11919931 · Granted Mar 5, 2024

Estimated economic value: $480,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Fusion proteins specific for CD137 and GPC32025
Fusion proteins specific for CD137 and GPC32025
Fusion proteins specific for CD137 and GPC32025
Proteins specific for CD1372025
Proteins specific for CD1372025
Proteins specific for CD1372025
Proteins specific for CD1372025
Lipocalin muteins with binding affinity for LAG-32023
Lipocalin muteins with binding affinity for LAG-32023
Lipocalin muteins with binding affinity for LAG-32023
Engineered T cells and uses therefor2022
Specific-binding polypeptides and uses thereof2022